About Auxenion Research AG

Auxenion Research AG is an early-stage biopharmaceutical company headquartered in Basel, Switzerland, focused on the discovery and early development of targeted oncology therapeutics. The company is built around a proprietary phenotypic drug discovery platform and a lead family of OXPHOS inhibitors aimed at drug-resistant cancers.

Unlike a traditional commercial business, Auxenion is designed to create value through protected intellectual property and stage-based monetization. Its model centers on advancing assets to defined development milestones, then licensing or selling them to larger pharmaceutical partners capable of taking them further.

Why the Business Needed a More Specialist Plan

Auxenion did not need generic startup copy. It needed a business plan that could explain a specialist oncology R&D model to investors, strategic partners, and potential licensees. That meant translating complex science into a commercially credible story covering market opportunity, monetization logic, development milestones, competitive positioning, and risk.

How We Built the Plan for Auxenion Research AG

Avvale developed a 39-page research-only business plan that translated the company’s scientific model into a structured commercial narrative. We positioned Auxenion around the actual value drivers of early-stage biotech: differentiated science, IP ownership, clear development inflection points, licensing readiness, and disciplined capital deployment.

The plan defined the business across three core pillars: drug discovery and preclinical development, intellectual property and asset monetization, and strategic partnerships and fundraising. It also clarified how the company intends to monetize assets after lead optimization, post-IND approval, or post-clinical proof of concept.

What the Business Plan Actually Covered

The completed plan went well beyond a simple company summary. It covered global and European oncology market sizing, the emerging OXPHOS inhibitor landscape, supply and demand dynamics, competitor benchmarking, licensing and exit timing, scientific and commercial risk, and a KPI framework tied to both development and business development progress.

It also established a phased path for the company: advancing the lead asset through preclinical proof of concept, moving into IND-enabling studies and candidate nomination, and progressing toward IND submission, early clinical preparation, and licensing or sale at strategic value-inflection points.

A Clearer Commercial Story for a Specialist Biotech Venture

The finished business plan gave Auxenion a more credible and usable strategic document than the original live case study suggests. Instead of broad technology-sector wording, the deliverable explained the company as a Basel-based oncology biotech building value through differentiated science, protected IP, and milestone-based licensing.

It clarified how the lead OXPHOS inhibitor fits into an underdeveloped but strategically important area of oncology, why the timing is commercially compelling, and how the broader platform can support repeated asset generation over time.

The Oncology Biotech Landscape

For research-led ventures, a strong business plan has to do more than describe the company. It must connect science, IP, funding, market demand, commercialization logic, and execution timing in one coherent document. That is what this Auxenion engagement required, and that is what the final plan was designed to deliver.